Comparative Effectiveness of Anti-TNF Agents for Crohn’s Disease in a Tertiary Referral IBD Practice

被引：0
|
作者：
Seema A. Patil
Ankur Rustgi
Patricia Langenberg
Raymond K. Cross
机构：
[1] University of Maryland School of Medicine,Division of Gastroenterology and Hepatology, Department of Medicine
[2] University of Maryland,Department of Epidemiology and Public Health, School of Medicine
[3] Veterans Affairs,undefined
[4] Maryland Heath Care System,undefined
来源：
Digestive Diseases and Sciences | 2013年 / 58卷
关键词：
Crohn’s disease; Anti-TNF therapy; Infliximab; Adalimumab; Certolizumab pegol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：209 / 215
页数：6
相关论文
共 50 条
  • [41] Comparative effectiveness of vedolizumab and ustekinumab in Crohn's Disease patients who failed anti-TNF treatment: Interrogating 1019 patients from the UK IBD BioResource
    Desoki, R.
    Balendran, K.
    Kapizioni, C.
    Shawky, R.
    Parkes, M.
    Raine, T.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I118 - I118
  • [42] TNF and anti-TNF agents in Behçet's disease
    KT Calamia
    Arthritis Res Ther, 5
  • [43] MULTI-CENTRE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB AS INDUCTION THERAPY IN ANTI-TNF REFRACTORY CROHN'S DISEASE
    Razanskaite, Violeta
    Michail, Stephanie
    Morgan, James
    Davies, Michael
    Storey, Daneil
    Watters, Christopher
    Penman, Douglas
    Swaminathan, Mira
    Sabine, Joseph
    Chapman, Adam
    Reilly, Ian
    Flanagan, Paul
    Bodger, Keith
    Subramanian, Sreedhar
    GUT, 2019, 68 : A100 - A100
  • [44] Comment Regarding "Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial"
    Calderon, Lina Posada
    Strasser, Mary Oakley
    Brant, Aaron
    GASTROENTEROLOGY, 2023, 165 (05) : 1306 - 1307
  • [45] Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery
    Dai, Cong
    Huang, Yu-hong
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (04) : 1421 - 1422
  • [46] Anti-TNF Agents in Behcet's Disease Treatment
    Tatlican, Semih
    TURKISH JOURNAL OF RHEUMATOLOGY, 2009, 24 (01) : 27 - 38
  • [47] Natalizumab is Effective in the Treatment of Moderate to Severe Crohn's Disease Unresponsive to Anti-TNFα Agents
    Elvanides, Harry S.
    Burchett, Mary
    Ingram, Karen R.
    Annis, Kim
    Arsenescu, Razvan I.
    de Villiers, Willem J.
    GASTROENTEROLOGY, 2010, 138 (05) : S698 - S698
  • [48] Risk of Infections with Anti-TNF Agents in Patients with Crohn’s Disease After Elective Surgery
    Cong Dai
    Yu-hong Huang
    Digestive Diseases and Sciences, 2022, 67 : 1421 - 1422
  • [49] What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
    Kabacam, Gokhan
    Toruner, Murat
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2010, 21 (01): : 107 - 112
  • [50] AMISELIMOD SAFETY PROFILE FOR CROHN'S DISEASE, STRATIFIED BY PREVIOUS TREATMENT WITH ANTI-TNF AGENTS
    D'Haens, Geert R. A. M.
    Slatkin, Neal
    Israel, Robert
    Heimanson, Zeev
    GASTROENTEROLOGY, 2020, 158 (03) : S1 - S1
12345